Lung cancer trials in China

In China 1144 Also abroad 2746

1,144 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Where
Changsha, Hangzhou, Shanghai
Age
18 years to 75 years
People
162
Run by
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
See details and how to joinNCT06424665
Phase 2Taking people
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
47
Run by
Sun Yat-sen University
See details and how to joinNCT06719700
No phaseTaking people
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Where
Beijing
Age
18 years to 85 years
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07291921
Phase 1Taking people
An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
24
Run by
Shanghai AbelZeta Ltd.
See details and how to joinNCT07444281
Phase 1Taking people
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Where
Shanghai
Age
18 years and over
People
19
Run by
Shanghai Chest Hospital
See details and how to joinNCT06663306
Phase 3Taking people
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Where
Beijing
Age
18 years to 80 years
People
134
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07443397
Phase 2Taking people
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Where
Beijing, Chongqing
Age
18 years and over
People
20
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07110103
No phaseTaking people
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
Where
Changchun
Age
18 years and over
People
900
Run by
The First Hospital of Jilin University
See details and how to joinNCT07439991
Phase 1/2Taking people
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Where
Beijing, Chengdu, Chongqing, Fuzhou, Haikou, Heilongjiang, Henan, Hunan, Shanghai
Age
18 years to 80 years
People
54
Run by
Sichuan Enray Pharmaceutical Sciences Company
See details and how to joinNCT07433283
No phaseTaking people
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Where
Shanghai
Age
18 years to 100 years
People
500
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07434518
Phase 2Taking people
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
Where
Chongqing
Age
18 years to 75 years
People
36
Run by
Chongqing University Cancer Hospital
See details and how to joinNCT07425795
Phase 1/2Taking people
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Where
Beijing
Age
8 years to 85 years
People
85
Run by
Essen Biotech
See details and how to joinNCT07410494
Phase 1/2Taking people
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Where
Beijing
People
83
Run by
Essen Biotech
See details and how to joinNCT07410676
Phase 1Taking people
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
Where
Beijing
Age
18 years to 80 years
People
24
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07413042
Phase 2Not yet taking people in China
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
Where
Guangzhou
Age
18 years to 75 years
People
45
Run by
The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07413952
Phase 1/2Not yet taking people in China
A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
Where
Shanghai
Age
18 years and over
People
48
Run by
Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT07414927
Phase 2Taking people
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
43
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07408635
No phaseNot yet taking people in China
Tubeless Strategy for Enhanced Recovery After Sublobar Resection
Where
Guangzhou
Age
18 years to 75 years
People
138
Run by
The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07409129
Phase 2Not yet taking people in China
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
Where
Shijiazhuang
Age
18 years to 75 years
People
84
Run by
Hebei Medical University Fourth Hospital
See details and how to joinNCT07410611
Phase 2Taking people
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
54
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07410975
Phase 2Taking people
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
Where
Shanghai
Age
18 years to 80 years
People
60
Run by
Fudan University
See details and how to joinNCT06943235
Phase 2Taking people
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Where
Nanjing
Age
18 years to 75 years
People
33
Run by
Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07082179
Phase 2Not yet taking people in China
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
Where
Beijing
Age
18 years to 75 years
People
10
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07402070
Phase 1/2Taking people
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Where
Baoding, Beijing, Bengbu, Cangzhou, Ch’ang-ch’un, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Dalian, Fuzhou, Ganzhou, Guangzhou, Ha’erbin, Hangzhou, Hanzhong, Harbin, Hefei, Henan, Hohhot, Jiangxi, Jilin City, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Qinhuangdao, Shanghai, Shantou, Shenyang, Shenzhen, Suzhou, Taiyuan, Taizhou, Tianjin, Tonghua, Weifang, Wenzhou, Wuhan, Wuhu, Xiamen, Xi’an, Xuzhou, Yantai, Yibin, Yinchuan, Zhengzhou, Zhenzhou
Age
18 years and over
People
400
Run by
Betta Pharmaceuticals Co., Ltd.
See details and how to joinNCT04930432
No phaseTaking people
Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
Where
Guangzhou
People
1,000
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07239063